Argenx to Continue Development of Autoimmune Disease Drug After Phase 2/3 Data

MT Newswires Live

2024/11/20

Argenx (ARGX) said Wednesday it will proceed with developing its experimental drug, efgartigimod subcutaneous, to treat idiopathic inflammatory myopathies in its ongoing phase 2/3 study.

The decision follows data from phase 2 results that showed a significant treatment effect in the total improvement score at Week 24 and improvements across key measures in patients treated with efgartigimod subcutaneous compared to placebo.

The company said it will continue to enroll patients across each of the three myositis subtypes in the study, including immune-mediated necrotizing myopathy, anti-synthetase syndrome, and dermatomyositis.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2484926491"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2484926491\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2484926491?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 19:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484926491","market":"fut","top_or_hot":-1,"title":"Argenx to Continue Development of Autoimmune Disease Drug After Phase 2/3 Data","media":"MT Newswires Live","content":"<html><body><p> Argenx (ARGX) said Wednesday it will proceed with developing its experimental drug, efgartigimod subcutaneous, to treat idiopathic inflammatory myopathies in its ongoing phase 2/3 study.</p><p>The decision follows data from phase 2 results that showed a significant treatment effect in the total improvement score at Week 24 and improvements across key measures in patients treated with efgartigimod subcutaneous compared to placebo.</p><p>The company said it will continue to enroll patients across each of the three myositis subtypes in the study, including immune-mediated necrotizing myopathy, anti-synthetase syndrome, and dermatomyositis.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Argenx to Continue Development of Autoimmune Disease Drug After Phase 2/3 Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArgenx to Continue Development of Autoimmune Disease Drug After Phase 2/3 Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-20 19:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Argenx (ARGX) said Wednesday it will proceed with developing its experimental drug, efgartigimod subcutaneous, to treat idiopathic inflammatory myopathies in its ongoing phase 2/3 study.</p><p>The decision follows data from phase 2 results that showed a significant treatment effect in the total improvement score at Week 24 and improvements across key measures in patients treated with efgartigimod subcutaneous compared to placebo.</p><p>The company said it will continue to enroll patients across each of the three myositis subtypes in the study, including immune-mediated necrotizing myopathy, anti-synthetase syndrome, and dermatomyositis.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2484926491","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484926491","pubTimestamp":1732103911,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Argenx  said Wednesday it will proceed with developing its experimental drug, efgartigimod subcutaneous, to treat idiopathic inflammatory myopathies in its ongoing phase 2/3 study.The decision follows data from phase 2 results that showed a significant treatment effect in the total improvement score at Week 24 and improvements across key measures in patients treated with efgartigimod subcutaneous compared to placebo.The company said it will continue to enroll patients across each of the three myositis subtypes in the study, including immune-mediated necrotizing myopathy, anti-synthetase syndrome, and dermatomyositis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","ARGX":"Argenx SE","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"Argenx将在2/3期数据后继续开发自身免疫性疾病药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARGX":0.9},"content_text":"Argenx (ARGX) said Wednesday it will proceed with developing its experimental drug, efgartigimod subcutaneous, to treat idiopathic inflammatory myopathies in its ongoing phase 2/3 study.The decision follows data from phase 2 results that showed a significant treatment effect in the total improvement score at Week 24 and improvements across key measures in patients treated with efgartigimod subcutaneous compared to placebo.The company said it will continue to enroll patients across each of the three myositis subtypes in the study, including immune-mediated necrotizing myopathy, anti-synthetase syndrome, and dermatomyositis.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}